Arbutus Biopharma (ABUS) Getting Somewhat Favorable News Coverage, Study Shows
Press coverage about Arbutus Biopharma (NASDAQ:ABUS) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Arbutus Biopharma earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.1452392894231 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Appili Therapeutics Appoints Seasoned Biotech Executive Ian C. Mortimer to its Board – Digital Journal (digitaljournal.com)
- Arbutus Biopharma Corp. breached its 50 day moving average in a Bullish Manner : ABUS-US : November 28, 2017 (finance.yahoo.com)
- Arbutus Announces Presentations at HepDART 2017 – GlobeNewswire (press release) (globenewswire.com)
- Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application to U.S. FDA for Patisiran (bctechnology.com)
Shares of Arbutus Biopharma (NASDAQ:ABUS) opened at $5.90 on Wednesday. The company has a current ratio of 11.03, a quick ratio of 11.03 and a debt-to-equity ratio of 0.08. Arbutus Biopharma has a 52-week low of $2.35 and a 52-week high of $8.25.
Several brokerages have recently weighed in on ABUS. JMP Securities reiterated an “outperform” rating and set a $13.00 price objective (up previously from $12.00) on shares of Arbutus Biopharma in a report on Wednesday, October 4th. ValuEngine upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Thursday, September 21st. Wedbush reiterated an “outperform” rating and set a $9.00 price objective on shares of Arbutus Biopharma in a report on Wednesday, September 20th. Leerink Swann reiterated a “market perform” rating and set a $5.00 price objective (up previously from $4.00) on shares of Arbutus Biopharma in a report on Tuesday, November 7th. Finally, Zacks Investment Research upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Tuesday, November 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $13.00.
In other news, insider Michael J. Sofia sold 10,000 shares of the business’s stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $8.00, for a total transaction of $80,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 10.00% of the company’s stock.
Arbutus Biopharma Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.